Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)news2024-05-15T13:02:51+00:00May 15th, 2024|Medical Device News Magazine|
